Sermorelin
Synthetic analogue of GHRH (amino acids 1-29). Stimulates the pituitary gland to release GH naturally, preserving negative feedback.
- Increased general well-being
- Improved body composition (long-term)
- Excellent safety profile
- Cost-effectiveIncrease in general well-being
- Cost-effective
- Flushing, mild headache.
Sermorelin is an analogue of GHRH (Growth Hormone Releasing Hormone) made up of the first 29 amino acids of the natural hormone, and is the oldest GH secretagogue studied for clinical use.
READ MORE
What it is (in plain language)
- It's an 'alarm clock' for your own growth hormone production. Instead of injecting synthetic GH, Sermorelin persuades your pituitary gland to produce more of its own hormone. It's a more natural and safer way to combat the signs of ageing, such as muscle loss and sagging skin.
Why do you appear online so much
- It is the basis of GH replacement therapy in anti-ageing clinics. It is valued for maintaining the natural cycles (pulses) of the hormone, avoiding the disconnection from the natural hormonal axis that occurs with direct injectable GH.
How it is framed today (pragmatic view)
- 1) Evidence: Decades of approved clinical use for growth deficiencies. 2) Objective: Vitality, body composition and skin health. 3) Risk: Very low; the main challenge is the short half-life, requiring frequent nocturnal administration.
How to use this form
- Read about the fasting administration protocol to maximise the nocturnal GH peak.
- Quick profile (curated by Subject 157)
- Class: Hormonal
- Status: Verified
- Use case: Hormonal
- Route: Injectable
- Tags: Injectable|GH|Wellness
- Half-life: ~10-20 mins
- Start: Fast
- Duration: ~2 hours
- Mechanism (high level)
Synthetic analogue of GHRH (amino acids 1-29). Stimulates the pituitary gland to release GH naturally, preserving negative feedback.
- Evidence (what the literature covers)
RANGE OF RESEARCH (Clinical/Wellness, Non-prescriptive):
Doses of 200mcg to 500mcg in the evening.
Level of Evidence: A (Extensive clinical use).
- Safety and harm-reduction (non-prescriptive)
Risks: Flushing, mild headache.
Interactions: Unknown.
- References (anchors)
- Prakash, A. (1999) - Sermorelin review in idiopathic GHD - https://doi.org/10.2165/00063030-199912020-00007 | PubMed:10419277
- Vance, M. L. (1997) - Sermorelin effect on GH pulsatility - https://doi.org/10.1210/jcem.82.5.3943 | PubMed:9141541
Note: Educational/research content. Does not constitute medical advice, diagnosis or prescription.
